August 9, 2007 - Hologic Inc. announced that, according to a recent independent peer-reviewed study published in the July issue of Radiology, computer aided detection correctly marked 99 (96.1 percent) of 103 consecutive asymptomatic breast cancers detected with digital mammographic screening, with an acceptable false marker rate (1.80 false CAD marks per patient). The CAD system (ImageChecker M1000 version 3.1) used in this study was from Hologic’s R2 Technology subsidiary.
Yang and co workers, from the Seoul National University Medical Research Center, reported that the R2 CAD system “marked all 44 breast cancers that manifested as microcalcifications only, all 23 breast cancers that manifested as a mass with microcalcifications and 32 (89 percent) of 36 lesions that appeared as a mass only.” “We are pleased that this study (the first to be published on R2 digital CAD by an independent medical facility) showed such strong results. Of particular note, CAD correctly marked the single invasive lobular carcinoma lesion and 67 of 71 (94.4 percent) of invasive ductal carcinomas, of which 22 had a component of DCIS. As digital mammography gains wider acceptance, R2’s CAD will continue to be a valuable tool to assist radiologists in the earlier detection of breast cancer”, said Dr. Ronald A. Castellino, R2 Technology’s chief medical officer.
Hologic|R2 continues to develop and refine it’s CAD solutions and is currently marketing ImageChecker V8.3 for digital mammography.
For more information: www.r2tech.com and www.hologic.com
June 06, 2023 
